MESI Landing Page 20.png

Reducing Cardiovascular Disease Incidence with MESI ABPI MD: A Critical Diagnostic Tool

CVDs are amongst the most common health problems in Australia; 1.2 million people were found to have cardiovascular diseases such as heart disease and strokes between 2014 and 2015. In 2017, the number of deaths was attributed to CVD—43,477—making it the second most common cause of death in the country.
These conditions are often linked to a variety of risk factors, including advancing age, genetic predisposition, gender, ethnicity, and other chronic diseases like diabetes and chronic kidney disease (CKD).

Common Complications of Cardiovascular Disease

CVD can lead to serious complications that affect a patient’s quality of life and survival rate. These include:
  • Heart failure: When the heart can no longer pump sufficient blood to meet the body’s needs.
  • Heart attack: A blockage in blood flow to the heart caused by a blood clot.
  • Stroke: Blocked blood flow to the brain resulting in damage.
  • Sudden cardiac arrest: The unexpected cessation of heart function.
  • Aneurysm: An abnormal bulge in the wall of a blood vessel, which can occur throughout the circulatory system.
  • Peripheral Arterial Disease (PAD), particularly Lower Extremity Arterial Disease (LEAD): This condition causes reduced blood flow to the legs, often leading to pain while walking.

Why Early Detection of PAD is Critical

Many patients with peripheral arterial disease remain undiagnosed for long periods. However, early detection will help to prevent and manage PAD. Regular checkups are a must, especially since 40-60% of patients with PAD also suffer from coronary artery disease or cerebral artery disease.

The ABI test is a good first step to help find PAD early. The American Heart Association (AHA) and the European Society of Cardiology (ESC) have both stated that ABI is a very useful tool in the assessment of heart health risks.

General practitioners and cardiologists should perform an ABI measurement annually for patients with coronary heart disease (CHD) and hypertension to identify PAD early and reduce the risk of severe cardiovascular complications.

How MESI ABPI MD Revolutionises PAD Detection

While traditional ABI testing involves using a Doppler probe, MESI ABPI MD offers a faster, simpler, and more accurate alternative. The test, which takes just one minute, involves simultaneous blood pressure readings from the arm and both legs, providing quick and reliable results.

The PADsense™ algorithm within the MESI ABPI MD device allows for detailed pulse waveform analysis, identifying severe cases of PAD. In cases where ankle pulses are absent or weak, the MESI ABPI MD highlights these issues, ensuring that healthcare professionals can take immediate action for the patient’s vascular health.

The Broader Impact of Cardiovascular Disease

Cardiovascular disease not only affects the heart health, yet it also affects the physical aspect of a person's health, mental and emotional well-being of an individual. A study conducted by Sarah Brealey of the British Heart Foundation indicated that 68% of the people experiencing heart problems reported feeling anxious, depression, or tearful; many felt fearful and lonely. Such mental and emotional challenges extend to the families and caregivers of patients, which goes to prove the importance of early help and preventive care.

MESI ABPI MD: A Step Towards Reducing Cardiovascular Disease Incidences

At EBOS Healthcare, we are committed to improving the detection and management of cardiovascular diseases. Our MESI ABPI MD Trial Platform is available to healthcare practitioners, providing an easy and effective way to screen for PAD in at-risk patients, ultimately reducing the incidence of CVD and improving patient outcomes.

Call us today for a FREE MESI ABPI MD Trial on 1800 269 534.